NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer
August 15, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trialShort-talk presentation at upcoming AACR Special...
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
NGM Biopharmaceuticals, Inc.
--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with...
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
June 30, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
-- William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors -- SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc....
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
June 23, 2022 16:05 ET
|
NGM Biopharmaceuticals, Inc.
--NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy, will be showcased in the fourth of a four-part...
NGM Bio to Participate in Upcoming Investor Conferences
June 02, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
May 24, 2022 16:05 ET
|
NGM Biopharmaceuticals, Inc.
--NGM707, NGM Bio’s most advanced myeloid reprogramming antibody product candidate, will be showcased in the third of a four-part series titled the “Explorer Series”-- SOUTH SAN FRANCISCO, Calif.,...
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
May 12, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®-- --All three of...
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
May 05, 2022 16:14 ET
|
NGM Biopharmaceuticals, Inc.
Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with...
NGM Bio to Participate in Upcoming Investor Conferences
April 20, 2022 16:05 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022
April 20, 2022 09:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...